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SUMMARY
The hippocampus in schizophrenia is characterized by both hypermetabolism and reduced size. It
remains unknown whether these abnormalities are mechanistically linked. Here, in addressing
these questions we used MRI tools that can map hippocampal metabolism and structure in patients
and mouse models. In at-risk patients, hypermetabolism was found to begin in CA1 and spread to
the subiculum after psychosis onset. CA1 hypermetabolism at baseline predicted hippocampal
atrophy, which occured during progression to psychosis, most prominently in similar regions.
Next, we used ketamine to model conditions of acute psychosis in mice. Acute ketamine
reproduced a regional pattern of hippocampal hypermetabolism, while repeated exposure shifted
the hippocampus to a hypermetabolic state with concurrent atrophy and pathology in parvalbumin-
expressing interneurons. Parallel in vivo experiments using LY379268 and direct measurements of
extracellular glutamate showed that glutamate drives both neuroimaging abnormalities. These
findings show that hippocampal hypermetabolism leads to atrophy in psychotic disorder and
suggest glutamate as a pathogenic driver.
INTRODUCTION
Previous research has demonstrated functional and structural and abnormalities in the
hippocampus of patients with schizophrenia and related psychotic disorders. Among the
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most prominent are hypermetabolism and volume reduction of the hippocampus as reflected
in neuroimaging studies (Heckers et al., 1998; Kawasaki et al., 1992; Malaspina et al., 2004;
Medoff et al., 2001; Molina et al., 2003; Steen et al., 2006).
The hippocampal formation is a complex structure comprised of different subregions
extending the posterior-to-anterior extent of the medial temporal lobe to form a neural
circuit (Small et al., 2011). Recent neuroimaging studies have shown that the CA1 and
subiculum in the anterior body of the hippocampus are differentially affected in
schizophrenia, as reflected by volume (Kuhn et al., 2012), shape (Csernansky et al., 1998;
Narr et al., 2004), and metabolic measures (Schobel et al., 2009b). The overlap between the
anatomical pattern of hippocampal hypermetabolism and apparent atrophy suggests that
these neuroimaging abnormalities might have a common pathophysiologic mechanism.
However, as these neuroimaging tools have not yet been applied within the same population
of subjects, the precise concordance between hypermetabolism and atrophy remains
unknown. Furthermore, as it is now understood that schizophrenia is a progressive brain
disease (Andreasen et al., 2011), the temporal sequence of these pathologic features remains
uncharted.
Accordingly, to map the spatial and temporal pattern of hippocampal metabolism and
structure, we longitudinally assessed subjects who fulfilled ‘clinical high-risk’ criteria using
magnetic resonance imaging (MRI) methods. Previous studies have shown that about 30%
of this enriched group of subjects with prodromal symptoms progress to psychosis (Fusar-
Poli et al., 2012). We previously reported that baseline MRI maps of cerebral blood volume
(CBV), an established hemodynamic correlate of basal metabolism (Gonzalez et al., 1995;
Raichle, 1983), predicts progression to psychosis (Schobel et al., 2009b). In the present
study we imaged subjects at baseline and after follow-up periods, using both CBV-fMRI and
structural MRI measures. The results show that hippocampal hypermetabolism antedates
atrophy and that over time an anatomical concordance emerges between the specific pattern
of hypermetabolism and atrophy.
The anatomical concordance of metabolism and structure suggested a common mechanism,
and based upon current glutamatergic theories (Lisman et al., 2008; Moghaddam and Javitt,
2012) we hypothesized that elevations in extracellular glutamate might act as a pathogenic
driver. This hypothesis was informed, in part, by prior observations in a mouse model
deficient in glutamate, developed to understand how alterations in the glutamatergic system
relate to schizophrenia-relevant neuroimaging and behavioral phenotypes (Gaisler- Salomon
et al., 2009). By fMRI, reductions in CBV were observed in the same subregions
characterized by hypermetabolism in schizophrenia; moreover this ‘inverse’ neuroimaging
phenotype was accompanied by behavioral and neurochemical phenotypes that were in all
cases the inverse of what typically characterizes animal models of schizophrenia. These
results were interpreted in the context of a growing number of studies suggesting that excess
extracellular glutamate may be a contributing factor in psychosis. Systemic administration
of Nmethyl-D-aspartate (NMDA) receptor antagonists provides proof of this principal.
These agents, induce both positive and negative symptoms of the disease in healthy
volunteers (Krystal et al., 1994) and exacerbate psychotic symptoms and cognitive
impairments in patients with schizophrenia (Malhotra et al., 1997). Moreover, in
experimental animals, NMDA antagonists elevate extracellular glutamate (Moghaddam and
Javitt 2012) and induce hypermetabolism in cerebral cortex as detected by CBV-fMRI
(Gozzi et al., 2007) at doses that induce behavioral and neurochemical abnormalities
homologous with schizophrenia (Bickel and Javitt, 2009; Jentsch and Roth, 1999;
Moghaddam et al., 1997; Mouri et al., 2007; Pinault, 2008).
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To test the hypothesis that excess glutamate drives hippocampal subregional
hypermetabolism and atrophy in psychosis, we used administration of the NMDA antagonist
ketamine in mice, where invasive technologies can be deployed to precisely map
extracellular glutamate within the hippocampal circuit. First, we used the same MRI tools
applied to human patients to show that that ketamine administration in rodents replicated the
specific anatomical pattern of hippocampal dysfunction in schizophrenia. We then
conducted a series of experiments utilizing an in vivo glutamate biosensor method (Hu et al.,
1994) in multiple hippocampal subregions to show that ketamine causes a regionally
preferential increase in extracellular glutamate, and that a glutamate-reducing agent
ameliorates this increase, as well as MRI-detected hippocampal hypermetabolism and
atrophy. Finally, we performed post-mortem analyses to determine histopathological
correlates of the neuroimaging phenotypes.
RESULTS
Mapping a neuroimaging pattern of hippocampal dysfunction during the emergence of
psychosis
Twenty five subjects at clinical high-risk for a psychotic disorder were imaged while
experiencing prodromal symptoms, and then 20 were re-imaged at clinical follow-up
totaling 80% of the original sample. One patient in the progressor group, and four patients in
the non-progressor group were lost to brain imaging follow-up, though no were lost to
clinical follow-up. The average follow-up period and interscan interval was 2.4 years.
During this time ten of the 25 subjects progressed to psychosis, and fifteen subjects did not
develop a psychotic disorder (Supplemental Tables 1 and 2). Subjects were comparable on
baseline demographic variables including age (t23=.7, p=.48), sex (Fisher’s exact p=1.0),
years education (t22=0, p=1) and follow-up interval (t18=.8, p=.76).
Mapping hippocampal CBV—Subjects were imaged at baseline and at follow-up using
the steady-state gadolinium-enhanced fMRI technique, as previously described (Moreno et
al., 2007). Based on our previous findings (Schobel et al., 2009b) we focused on the anterior
aspect of the hippocampal formation. For each subject, mean CBV was measured from the
following hippocampal subregions—entorhinal cortex (EC), dentate gyrus (DG), CA3, CA1,
and subiculum (SUB). A repeated-measures analysis of variance with subregion (EC, DG,
CA3, CA1, and SUB) and side (left, right) as within-subject factors and outcome
(progression to psychosis vs. non-progression) as between-subjects factor revealed a
subregion by progression to psychosis interaction (F4,18=3.1, p=.04); Post-hoc t tests
revealed increases in CA1 subfield CBV averaged across sides (t23=2.7, p=.01), and, in
particular, increases in left-sided CA1 subfield CBV (t23=3.5, p=.002).
To test for longitudinal changes in CBV from baseline to follow-up, a repeated measures
analysis with time (baseline and follow-up) and subregion (EC, DG, CA3, CA1, and SUB)
as within-subjects factors and progression status (psychosis vs. not) as a between-subjects
factor was used. The multivariate component of the analysis identified a significant
subregion by time by group interaction (F4, 13=3.5, p=.04). Post-hoc t-tests revealed this
interaction to be driven by CBV increases in subiculum from baseline to follow-up
bilaterally in the progressor group (t18=3.7, p=.002); increases in CA1 CBV did not change
significantly from time 1 to time 2, remaining relatively higher in the progressor group at
both baseline (t23=2.7, p=.01) and follow-up (t18=3.1, p=.006). EC, DG and CA3 were not
significantly different between groups at baseline or follow-up. Antipsychotic or
antidepressant drug exposure had no effect on CBV values in this analysis (Figure 1A).
To confirm that hippocampal hypermetabolism is predictive of psychosis, we entered
hippocampal left anterior CA1 CBV into a Cox regression model, controlling for
Schobel et al. Page 3













demographics and follow-up interval, with time to psychosis as the dependent variable. Left
anterior CA1 CBV powerfully predicted time to psychosis in the Cox model (Wald (t1)=8.5,
p=.003). We further explored whether brain metabolism or symptoms were more powerful
predictors of outcome. Similar to other larger prodromal cohort studies (Cannon et al.,
2008), unusual thought content (Wald(t1)=2.9, p=.09) suspiciousness, (Wald(t1)=2.9, p=.08)
and conceptual disorganization (Wald(t1)=3.5, p=.06) also predicted time to psychosis at a
trend level when entered separately into this model. When behavioral variables were entered
together into the predictive model with left anterior CA1 CBV, brain metabolism maintained
its predictive strength (Wald(t1)=8.8, p=.003), whereas behavioral measures were no longer
predictive of clinical outcome (all p’s >.33), suggesting that left CA1 CBV is a more
sensitive predictor of clinical outcome to first episode psychosis than subthreshold psychotic
symptoms.
Mapping hippocampal structure—In the same subjects, MRI was used to map
hippocampal structure and generate measures of hippocampal volume and hippocampal
shape as previously described (Schobel et al., 2009a; Styner, 2003). At the initial
assessment, to test for baseline differences in hippocampal volume, a repeated-measures
analysis of variance with side (left, right) as within-subject factors and outcome (progression
to psychosis vs. non-progression) as between-subjects factor revealed no main effect of
progression status (F1,22=.96, p=.36) and no side-by-conversion interaction (F1,22=1.1, p=.
30). To test for hippocampal atrophy over time, a repeated measures analysis with time
(baseline and follow-up) and hippocampal volume as within-subjects factors and
progression status (psychosis vs. not) as a between-subjects factor, controlling for baseline
hippocampal volume, revealed a group by time interaction (F1,16= 17.6, p=.001), in which
the hippocampal volume of progressors to psychosis declined bilaterally (t18=4.6, p<.001)
(Figure 1B). Antipsychotic or antidepressant exposure had no effect on hippocampal
volumes at either time 1 or time 2 between groups.
To map the site of within the hippocampus where atrophy where occurred and whether it
was localized to a specific hippocampal subregion, morphological analysis of the
longitudinal assessments was performed (Figure 1C, 1D). Compared to non-progressors,
progressors had volume loss localized to the CA1 and subiculum subregions, which were
most prominent in the anterior body of the left hippocampus (Figure 1C, 1D).
The relationship between hippocampal CBV and atrophy—To investigate the
spatiotemporal relationship between hippocampal CBV acquired at baseline and subsequent
hippocampal structural changes, we first visualized the left hippocampal morphometric
shape result (Figure 1C) in a magnified fashion, focusing upon the extent of the long axis of
the hippocampal body containing the left CA1 subfield (Figure 2A). We then generated
baseline CA1 CBV values in subjects along the extent of the same area of the long axis of
the hippocampal body. CBV values from the posterior to anterior extent of the hippocampal
body were entered into a single multivariate analysis of variance with hippocampal long axis
CBV as within-subjects factors and progression status (psychosis vs. not) as a between-
subjects factor, controlling for demographics (both left and right sides included in the
analysis; Figure 2B shows an example of left long axis CA1 CBV of the hippocampal body
from posterior to anterior in an individual subject). CBV increases at baseline were localized
to the two most anterior slices of the left body of the hippocampus (F1=10.8, p=.002;
F1=3.6, p=.07; respectively) (Figure 2C). Taken together, the results show an anatomical
overlap between left anterior hippocampal body CA1 CBV acquired at baseline and the most
significant morphologic shape change across the transition to psychosis found in left anterior
hippocampal body CA1. To confirm this spatiotemporal relationship, we tested the
association of baseline hippocampal CBV along the long axis to subsequent hippocampal
volume change. Higher baseline CBV values in left CA1 in the anterior hippocampal body
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predicted subsequent hippocampal atrophy at follow-up (beta=−.63, t=2.53, p=.03), an
association not found in the posterior body (beta=−.17, t=.76, p=.45) and mid-body CA1
subfields (beta=−.3, t=1.2, p=.24) (Figure 2D). Moreover, this association was specifically
found between elevated baseline left anterior CBV values and subsequent left hippocampal
volume decrease (beta .58, t=2.9, p=.01).
Mapping a neuroimaging pattern of hippocampal dysfunction induced by acute ketamine
administration in mice
Male C57B6 mice aged 50–70 days postnatal (n=9 per group), an age range analogous to
young adulthood in the human (Laviola et al., 2003), were used for this experiment. While
the mice were stably anesthetized, we administered an acute ketamine (30mg/kg) or saline
challenge; CBV was then measured within subregions (EC, DG, CA3, CA1, SUB) of the
ventral hippocampal body at 16, 32, and 48 min post-challenge using previously described
CBV-fMRI imaging methods (Moreno et al., 2006). A mixed ANOVA showed an
interaction between drug challenge and post-injection time, with ketamine-induced increases
in CBV observed in CA1 (F4,13=4.1, p=.02) (Figure 3A) and subiculum (F4,13=3.8, p=.03)
subregions (Figure 3B). Planned pairwise comparisons showed significant increases
(relative to pre-injection baseline) at 16 min (CA1: t8=4.3, p=.003; SUB: t8=4.8, p=.001)
which persisted at a trend level at 32 min (CA1: t8=1.9, p=.09;SUB t8=2.1, p=.07) (Figure 3
A–B) For both CA1 and subiculum, saline injection produced no significant increases in
CBV relative to pre-injection baseline. Moreover, there were no statistically significant
effects of ketamine (relative to baseline or saline) within EC, DG or CA3 (Figure 3 C–E).
Mapping a neuroimaging pattern of hippocampal dysfunction after repeated ketamine
administration in mice
Mapping hippocampal CBV—To model episodic neurochemical conditions that may
precipitate psychosis, we exposed C57B6 male mice ages 35–45 days (n=6–10 per group),
to three times weekly exposure to ketamine (8mg/kg, 16mg/kg, and 32mg/kg dose groups)
or saline for one month (total 12 doses per group) (Supplemental Figure 1). The age range is
considered to be analogous to the period from mid-adolescence through young adulthood in
human (Laviola et al., 2003), during which time the risk for psychosis rises sharply in males
(Paus et al., 2008). At the end of the 1-month treatment (at age 65–75 days), following a 48-
to 72-hour washout period, we imaged basal CBV. An ANOVA revealed a main effect of
drug dose on basal hippocampal CBV at one month (F3,28=3.3, p=.035); planned pair-wise
comparisons of each ketamine dose group to saline showed that repeated ketamine led, with
an inverse “U” shaped dose function, to an increase in basal-state CBV preferentially in the
CA1 subfield (Figure 4A). Specifically, relative to saline administration, exposure to
intermittent ketamine 8mg/kg resulted in increases in basal CBV in the CA1 subfield
(t3=4.3, p=.02); exposure to the 16/mg dose resulted in increases in the CA1 subfield
(t9=2.3, p=.05) as well as trends for increases in the CA3 subfield (t9=1.8, p=.08) and
subiculum (t9=1.9, p=.09). Exposure to the 32mg/kg dose resulted in less robust increases in
basal CBV across subregions (all p’s>.2).
Mapping hippocampal structure—Structural imaging was performed on the same mice
used in the repeated ketamine study at baseline (at age 35–45 days, n=6–10 per group) and
following the 1-month treatment (at age 65–75 days). For this study, for total forebrain and
total hippocampal volume were determined using structural T2-weighted horizontal MRI
images (24 slices, rostral to dorsal, 86µM in plane resolution, 500 µM slice thickness). Not
surprisingly, during acute exposure there was no change in hippocampal volume (F3, 26=.64,
p=.59). We next compared hippocampal volume change over the one month amongst the
four groups, controlling for whole brain volume. Results revealed a main effect of group on
hippocampal volume change (F3, 26=12.9, p<.001). Post-hoc tests showed the 16mg/kg
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(t18=5.3, p<.001) and 32mg/kg (t14=3.8, p=.002) groups had a relative loss of volume;
specifically mice treated at these doses showed no growth or a loss of hippocampal volume
over one month relative to the saline-exposed group, which showed increases in volume
over the month (Figure 4B). To map the site of negative hippocampal growth,
morphological analysis of the longitudinal assessments was performed. Compared to the
saline group, mice exposed to 16mg/kg had volume loss localized to the ventral portion of
hippocampal body (Figure 4C).
Gross hippocampal structure was also assessed post-mortem in fixed, immunostained tissue
in a subset of mice from this study and the related experiment assessing the effect of
cotreatment with LY379268 (see below). For these studies, we systematically sampled
coronal sections through the body of the hippocampus, calculating average cross-sectional
area of blocks matched across groups for location within hippocampus. Guided by the
imaging findings, we divided the body into a rostrodorsal portion (1.0 to 2.4 mm posterior to
Bregma; rostral to the emergence of the ventral hippocampus) and caudoventral portion (2.5
to 4.0 mm posterior to Bregma, including ventral hippocampus). An omnibus analysis
including the three repeated drug treatment groups (saline-only control, saline co-treatment
with ketamine [16 mg/kg], and LY379268 [10 mg/kg] co-treatment with ketamine [16 mg/
kg]) showed a significant interaction between drug condition and position within the
hippocampus (F2,14 = 4.7, p < 0.05). Planned comparisons between the saline control and
repeated ketamine groups revealed that while there was no difference between drug groups
for the rostrodorsal hippocampus (t8 = 0.26, 1-tailed p > 0.4), the caudoventral hippocampus
was reduced in size in the repeated ketamineexposed mice relative to saline (t8 = 1.93, p < .
05) (Figure 4D).
Excess glutamate mediates the psychosis-associated neuroimaging pattern of
hippocampal dysfunction
To determine whether extracellular glutamate mediated the acute effect of ketamine on
hippocampal CBV, ketamine 30mg/kg or saline was administered via an i.p. catheter under
the same experimental conditions used in the acute ketamine CBV experiments above, and
the extracellular glutamate response was recorded in specific hippocampal subregions in
vivo following implantation of an amperometric glutamate biosensor (Hu et al., 1994). An
ANOVA showed a significant ketamine-evoked increase in hippocampal glutamate
(F3,24=4.6, p=.01); planned comparisons showed increases in the CA1 (t11=2.4, p=.03) and
SUB (t10=2.5, p=.03) relative to the EC which showed no increase following ketamine
(Figure 5A, 5B).
To determine whether increases in extracellular glutamate were necessary for
ketamineevoked hippocampal hypermetabolism to occur, we pre-treated mice with
LY379268(10mg/kg), a drug which reduces neuronal glutamate release through activation of
presynaptic mGlur2/3 receptors (Lorrain et al., 2003; Monn et al., 1999) Mice were pre-
treated for five days with LY379268 or saline prior to recording the extracellular glutamate
response or CBV response to acute ketamine challenge 30mg/kg. An ANOVA revealed that
L379268 blocked the ketamine-evoked glutamate elevation in CA1/SUB (F1,11=5.5, p=.04)
(Figure 5C). At this glutamate-suppressing dose, LY379268 also prevented ketamine-
induced increases in CA1/SUB CBV (overall F2,27=21.7, p<.001); planned comparisons of
LY379268 to SAL pretreatment (p<.001) (Figure 5D).
To determine whether glutamate mediated the induction of the hypermetabolic state and
relative volume loss observed with repeated intermittent ketamine exposure, mice were
administered either saline or LY379268(10mg/kg) one hour prior to receiving each ketamine
(16mg/kg) treatment, totaling 12 (3 weekly) co-treatments over one month. Prior to endpoint
CBV and structural hippocampal imaging, all animals were withdrawn from treatment for 48
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hours. LY739268 prevented ketamine-induced basal increases in CBV throughout the
trisynaptic circuit and subiculum (DG F1,17=7.0, p=.01; CA3 F1,17=5.2, p=.04; CA1
F1,17=4.3, p=.05; SUB F1,17=6.1, p=.03; (Figure 6A). At this basal hypermetabolism-
suppressing dose, LY379268 also prevented the repeated ketamine-induced hippocampal
volume decrease over the one month exposure (F1,17=11.7, p=.003) (Figure 6B). Additional
morphometric analyses revealed that the region showing the most consistent relative
protection overlapped with midbody CA1 and subiculum (Figure 6C). This was consistent
with the post-mortem analysis (performed as described above) which showed an effect of
LY379268 co-treatment on hippocampal structure following repeated ketamine (Figure 6D).
Specifically, while there were no group differences observed in the rostrodorsal
hippocampus, the size of the caudoventral hippocampus was larger in repeated ketamine-
treated mice receiving LY379268 co-treatment than mice co-treated with saline (t12 = 2.1,
1-tailed p<.05).
GABAergic interneuronal markers are linked to the neuroimaging pattern of hippocampal
dysfunction
To further investigate circuit mediators of the above effects of repeated ketamine, we
quantified the density of the parvalbumin-positive (PV+) subpopulation of GABAergic
interneurons in the CA fields of three groups from the longitudinal treatment studies (saline/
saline [saline control], saline/ketamine16mg/kg, LY37926810mg/kg/ketamine 16mg/kg). A
general linear model showed significant differences in PV+ cell density across treatment
groups (Wald Chi-Square [df=2] = 8.1, p <.05). Pairwise comparisons (Wald) revealed that
repeated ketamine exposure (saline/ketamine16mg/kg group) led to significant decreases in
PV+ cell density relative to the saline control group (p <.01) (Figure 7A). PV+ cell density
in the LY379268 was intermediate, not differing significantly from either saline control or
the saline/ketamine group (Figure 7A). Interestingly, there was a strong trend across the
three groups for decreases in PV+ cell density (relative to the mean saline control value) to
correlate with increases in basal CA1 CBV observed after repeated ketamine exposure (r=.
49, p=.06) (Figure 7B). In turn, this abnormal increase in basal CA1 CBV was significantly
related to hippocampal volume loss (r=.57, p=.006) (Figure 7C).
DISCUSSION
Schizophrenia characteristically has a gradual onset beginning with a prodromal stage and
culminating with psychotic symptoms. Neuroimaging studies have demonstrated
pathological involvement of the hippocampal formation in schizophrenia with structural and
functional imaging techniques. These findings pose questions about the fundamental
relationship between hippocampal metabolism and structure during the onset and course of
schizophrenia. Our longitudinal study of prodromal patients revealed a spatiotemporal
pattern of hippocampal dysfunction that progresses in the transition from prodromal
symptoms to psychosis. During prodromal pre-psychotic stages hypermetabolism occurs
preferentially in the CA1 subregion of the hippocampus in the absence of structural
differences. As patients progressed to syndromal psychosis, hypermetabolism spread from
CA1 to the subiculum and, importantly, hippocampal volume reduction became evident. A
precise spatial concordance was observed between the anatomical pattern of
hypermetabolism and atrophy, occurring in the left CA1 and subiculum in the anterior
hippocampal body.
This anatomical concordance suggested a common upstream mechanism, so informed by
previous studies, we used the NMDA antagonist model of psychosis to test the hypothesis
that an elevation in glutamate acts a pathogenic driver. Acute systemic administration of
NMDA antagonists such as ketamine and phencyclidine recapitulate many of the features of
schizophrenia in humans, and in experimental animals elevates extracellular glutamate at
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doses that produce schizophrenia-relevant changes in behavior (Krystal et al., 1994;
Moghaddam and Javitt, 2012). Moreover, chronic or repeated exposure to NMDA
antagonists produces schizophrenia-relevant cognitive deficits (Jentsch and Roth, 1999) and
is associated with cortical gray matter loss in humans (Liao et al., 2011). Previous studies,
however, have not mapped ketamine’s effect on glutamate levels within the hippocampal
circuit. Here, acute ketamine administration produced a gradient of hippocampal
hypermetabolism comparable to that observed in the psychosis-stage of schizophrenia.
Moreover, chronic administration of ketamine for one month caused a shift in the state of
the hippocampus to hypermetabolism, atrophy, and down-regulation of PV+ interneurons,
all of which match the anatomical pattern of hippocampal dysfunction observed in patients.
We tested the hypothesis that increases in extracellular glutamate are required to produce
these neuroimaging phenotypes in three experiments in the rodent model: First, we found
that ketamine-evoked increases in extracellular glutamate mirrored the evoked fMRI pattern,
with preferential changes found in the CA1 subfield and subiculum subregion. Second, we
established a mechanistic link by showing that pre-treatment with a glutamate mGluR 2/3
agonist known to inhibit glutamate release blocked the ability of ketamine to evoke excess
extracellular glutamate and increases in CBV. Third, when studied longitudinally, co-
treatment with the glutamate release-limiting drug protected against the effects of repeated
ketamine on the PV+ interneurons and prevented the associated shift to basal
hypermetabolism and hippocampal atrophy. Notably CA1 and subicular subfields in the
hippocampal body were most affected with an overall anatomical pattern homologous with
that found for progression to psychosis in the human study.
The mGluR 2/3 agonist was an optimal choice to provide this mechanistic link because of its
selectivity in limiting glutamate efflux, and its ability to block the behavioral and cognitive
abnormalities produced by psychotomimetic drugs (Cartmell et al., 1999; Imre et al., 2006;
Krystal et al., 2005; Moghaddam and Adams, 1998). A range of studies now support the
hypothesis that glutamate metabolism and neurotransmission play a critical role in driving
the cognitive and behavioral disturbances of psychosis (Moghaddam and Javitt, 2012). In
the context of systemic NMDA receptor hypofunction, the condition modeled here, NMDA
receptor blockade has been shown in neocortex to increase glutamate efflux (Greene, 2001;
Moghaddam and Javitt, 2012) thereby increasing metabolic demand and blood flow
(Douglas L. Rothman, 2002; Pellerin and Magistretti, 1994). A similar cascade is likely to
operate in the hippocampus. Differential regional vulnerability of NMDA receptor blockade
may be mediated at a molecular level by the relatively high density of NMDA and AMPA
receptors in CA1 relative to other hippocampal subregions (Coultrap et al., 2005). AMPA
receptors in particular may play an important role in the consequent synaptic and
hemodynamic state (Moghaddam et al., 1997).
The effect of repeated ketamine on PV+ GABAergic interneurons observed here is
consistent with previous studies showing that NMDA antagonists lead to metabolic stress,
morphologic changes, and down-regulation of PV expression in cortical neurons (Behrens et
al., 2007; c.f. Benneyworth et al., 2011; Keilhoff et al., 2004; Vutskits et al., 2007). Further
research is needed to relate our results to postmortem findings in schizophrenia, which have
shown abnormalities in hippocampal GABAergic interneurons (Heckers and Konradi,
2010), as well as defects in AMPA-kainate and NMDA receptors (Gao et al., 2000;
Harrison, 2004; Law and Deakin, 2001). While our findings do not speak to whether acute
NMDA blockade on GABAergic interneurons induces a hyperglutamatergic state (see
models in Greene, 2001; Lisman et al., 2008; Moghaddam and Javitt, 2012), they provide
support for a complementary model: that chronic down-regulation of function in these
interneurons caused by a ‘toxic’ process modeled by repeated episodes of NMDA receptor
hypofunction may contribute to the hypermetabolic state observed in early psychosis.
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The current study supports the hypothesis that downregulation of hippocampal interneurons
may have significant feed-forward excitation of the hippocampal trisynaptic circuit as
originally hypothesized by Benes (Benes, 1999). Subsequent elevations in extracellular
glutamate may drive further hypermetabolism, progressive interneuronal pathology, and
eventual atrophy in the CA1 and subiculum. Consistent with this hypothesis, recent in vivo
studies using magnetic resonance spectroscopy (MRS) suggest that elevations in glutamate
might be characteristic of incipient psychosis in schizophrenia and associated with emergent
psychotic symptoms in healthy comparison subjects receiving acute ketamine challenge (de
la Fuente-Sandoval et al.; Stone et al., 2012). Currently, however, MRS does not possess
sufficient spatial resolution to measure glutamate in individual hippocampal subregions.
In addition to clarifying mechanisms of disease, the results of our study have several clinical
implications. CA1 hypermetabolism may be a possible state-specific biomarker of
prodromal and early psychotic disorders. As with other progressive disorders of the brain,
such as Alzheimer’s disease for example, early detection during prodromal stages, when the
disease is restricted to relatively confined areas of the brain, has emerged as an important
goal for improving therapeutic efficacy. By showing that hypermetabolism occurs before
atrophy, our results reinforce this concept, because reversing functional defects are likely
easier before the loss of brain tissue. Moreover, our results demonstrate that regulating
excess extracellular glutamate and reducing abnormal hippocampal hypermetabolism is
protective of hippocampal volume, one of the first and foremost regions to show volumetric
loss in schizophrenia (Steen et al., 2006).
Because the glutamate-driven metabolic and structural imaging phenotypes identified in the
current study are associated with the emergence of psychosis, we hypothesize that regulating
glutamate may be particularly effective during early stages of schizophrenia, a factor not yet
considered in recent clinical trials. Notably, glutamate-reducing agents include approved
drugs such as lamotrigine or gabapentin, as well as the experimental compound LY404309.
It is possible, therefore, to design a study in subjects at clinical high risk for psychotic
disorders to test whether glutamate-regulating drugs can normalize hippocampal
hypermetabolism, protect hippocampal volume, and prevent progression to threshold
psychotic disorder from prodromal stages of disease.
EXPERIMENTAL PROCEDURES
HUMAN STUDIES
Subjects and clinical assessment—Eligibility for study participation and prodromal
symptom severity were ascertained using the Structured Interview for Prodromal Syndromes
and Scale of Prodromal Symptoms (SIPS/SOPS)(Miller et al., 2003) as previously
described(Schobel et al., 2009b). Participants were assessed quarterly for conversion to
psychosis using the SOPS, and its Presence of Psychosis (POPS) criteria (Miller et al.,
2003). All aspects of the study including clinical assessment and imaging protocols were
approved through Columbia University’s IRB and the New York State Psychiatric Institute.
Written informed consent for subjects over age 18 years or written child assent with written
parental consent for subjects under 18 years was obtained after complete description of the
study procedures.
Hippocampal cerebral blood volume—As previously reviewed, the use of the contrast
agent gadolinium to map cerebral blood volume (CBV) with MRI is a basal state functional
imaging approach that provides high spatial resolution (Lin et al., 1999). Cerebral blood
volume maps were generated according to methodology as previously described on a Philips
1.5 T scanner (Moreno et al., 2007). Post-gadolinium enhanced images were aligned to pre-
gadolinium images in SPM5. Subtracted images (Post minus pre) were then divided by the
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contrast-induced difference in signal measured from the superior sagittal sinus (average
value of sagittal sinus used in calculation). An investigator blind to subject grouping
performed all imaging processing. Of note, all eighteen of the original clinical high-risk
participants that were a part of the baseline sample described in Schobel et al 2009 were
included in the present manuscript, with n=7 additional cases ascertained at baseline and
follow-up, to bring the study to a total n=25 baseline cases and n=20 completing the
longitudinal follow-up. All imaging cases were reanalyzed by a single blinded rater for the
present manuscript. Strict anatomic criteria for hippocampal subregions along the
hippocampal long axis were used to identify brain subregions as previously described
(Schobel et al., 2009b).
Hippocampal structure and morphometry—Hippocampal volumes were segmented
from the pre-contrast T1 weighted images as previously described using ITK-SNAP
(Schobel et al., 2009a; Yushkevich et al., 2006). After validation, these segmented volumes
were preprocessed and smoothed (Morey et al., 2009). Point-based models were obtained
via spherical parameterizations, and subsequent SPHARM-PDM representation. For more
detail of the 3D hippocampal shape representation, please refer to (Styner et al., 2003;
Styner, 2003). Statistical analysis was carried out on the aforementioned point-based models
as described below.
Statistical Analysis—The statistical models used to analyze the data for clinical studies
are found in Supplemental Experimental Procedures.
RODENT STUDIES
Subjects—A total of eighty-eight C57/BL6 (Taconic biosciences) male mice aged 50–70
days were used for the acute ketamine experiment. For the longitudinal study, we used forty-
two C57/BL6 mice that were (Taconic, Germantown, NY) aged 35–45 days at the beginning
of treatment, and imaged and processed for histology at 65–75 days. All animals were
housed 5 to a cage in a vivarium maintained on a 12 hr light/dark cycle. Experiments took
place during the light portion of the cycle, and food and water were available ad libitum. All
procedures were approved by the Columbia University and New York State Psychiatric
Institute Institutional Animal Care and Use Committees.
Drug study design—Ketamine (VedCo, St. Joseph, MO; 100 mg/kg concentration) was
diluted to 0.8–3.2 mg/ml and injected at a volume of 10 ml/kg body weight. It was chosen
on the basis of its psychotomimetic properties and wider use in (and thus translatability to)
humans than other NMDA antagonists. LY379268 (Tocris, Ellisville, MO) was chosen on
the basis of its function as an agonist at presynaptic glutamate metabotropic 2/3 receptors
and ability to inhibit synaptic glutamate release (Lorrain et al., 2003; Moghaddam and Javitt,
2012; Monn et al., 1999). For acute experiments, ketamine (30mg/kg) or saline challenge
was administered after baseline measurement of CBV or extracellular glutamate. For acute
drug pre-treatment studies, LY379268 (10mg/kg) vs. saline was administered
intraperitoneally (i.p.) once per day for five days prior to measurement of hippocampal CBV
or extracellular glutamate. For longitudinal study of intermittent repeated ketamine
exposure, mice were treated 3 times per week with saline (10 ml/kg, s.c.) or ketamine (8, 16
or 32 mg/kg, s.c.). For the drug co-treatment longitudinal experiment, animals were
administered LY379268 (10 mg/kg, s.c.) 30 minutes prior to each ketamine treatment
(16mg/kg, s.c) three times per week for one month. Following the month of treatment, mice
were imaged in the drug-free condition after a 48-hr drug washout period.
Hippocampal cerebral blood volume—High-resolution rodent CBV maps (86 µm)
were generated as previously described (Moreno et al., 2006; Moreno et al., 2007). After
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baseline CBV values were established, mice received either saline or ketamine as described
above and three 16-min post-challenge image sequences were obtained.
Hippocampal structure and morphometry—MRI volumes of C57B6 male mice from
each group were quantified at baseline (ages 35–45 days, n=6–10 per group) and at follow-
up (ages 65–75 days) for total forebrain and total hippocampal volume using structural T-2
weighted horizontal MRI images (24 slices, rostral to dorsal, 86µM in plane resolution, 500
µM slice thickness). Volumes were calculated by using a region-of-interest technique from
dorsal to rostral at the first appearance of cortex and hippocampus, respectively, following
the external boundary of mouse cortical mantle and hippocampus proper excluding
entorhinal cortex (Figure 4C). Rodent morphometry was conducted within a voxel-based
framework as described in Sawiak et al (Sawiak et al., 2009). Briefly, a unified
segmentation approach was implemented in SPM5 (Wellcome Department of Clinical
Neurology, London; http://www.fil.ion.ucl.ac.uk). Affine registered images were
transformed to atlas space and assigned a grey matter (GM) probability distribution
modulated by the Jacobian determinant of the transformation. Manually segmented
hippocampal ROIs were used to conduct small volume correction in statistical analyses.
Statistical analysis was performed in a factorial framework implemented in SPM5, with
treatment group as the between subject factor and time as within subject factor. Small-
volume correction was applied using the hippocampal ROI generated above. Family-wise
error (FEW) multiple-comparison correction was applied to all statistical tests with a
corrected height threshold of p=.05. Surface renderings of whole-brain and hippocampus
ROIs were generated in 3D Slicer (www.slicer.org) using a volume ray casting rendering
equation. Maximum intensity projections of T- and F- statistic maps were rendered and
overlayed onto the ROI isosurfaces using the volume render module in 3D Slicer.
Measurement of extracellular glutamate—The glutamate biosensor (model 7004,
Pinnacle Technologies; Lawrence, KS) was established to be sensitive to micromolar
concentrations of glutamate, able to detect rapid changes in extracellular glutamate efflux
(<0.5sec response), selective for glutamate, and sufficiently small (130 µM dimension
sensing probe) to selectively measure changes within hippocampal subregions (see Hu et al.,
1994). On the morning of the experiment, glutamate biosensors were calibrated against
glutamic acid using a 3-step concentration curve applied over three minutes. The selectivity
of the biosensor response was then tested by administration of 125mM of ascorbic acid and
tracing observed over an additional three minutes. After pre-calibration, the biosensors were
rinsed in ultra-pure H2O and then immediately implanted via the arm of the stereotax for in-
vivo recording. Sensitivity of the biosensor response (at least 3nA per 10 µM glutamic acid),
stability of the response, as well as a non-response to ascorbic acid were required for the
biosensor to be inserted for in vivo experiments.
Mice were anesthetized with chloral hydrate (400mg/kg) and placed in a stereotax with
heating pad post-induction, at which time a 0.6mm i.p. catheter for drug delivery was
inserted. Calibrated biosensors were then directly inserted into the ventral hippocampus and
connected to the potentiostat for in-vivo recording. Following baseline stabilization of
extracellular glutamate signal over one hour, ketamine 30mg/kg or saline was administered
via the i.p. catheter and extracellular glutamate response recorded from each hippocampal
subregion location over the following 30 minutes (Bregma coordinates EC A-P 4.7, M-L
3.0, D-V 4.0; Dentate Gyrus A-P 3.4, M-L 2.7, D-V 3.8; CA1 subfield A-P 3.5, M-L 3.25,
D-V 4.2; Subiculum A-P 3.9, M-L 3.25, D-V 4.2.) Post-experiment, animals were removed
from the stereotax, overdosed with chloral hydrate and euthanized by cervical dislocation.
Brains were post-fixed in paraformaldehyde (4%), cryoprotected, cryosectioned, thaw
mounted, dried, stained with a mixture of cresyl violet and neutral red, dehydrated/defatted
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and cover-slipped. Probe placements were verified according to the atlas of (Paxinos and
Franklin, 2001) (Supplemental Figure 2).
Histology and estimation of PV+ cell counts and hippocampal cross-sectional
area—In a subset of the mice used for the longitudinal study, brains were fixed via
transcardial perfusion of buffered saline followed by buffered 4% paraformaldehyde. The
brains were then sectioned with a vibratome or cryoprotected and cryosectioned. Coronal 40
micron-thick sections through hippocampus, from the anterior pole to through the posterior
extent of the CA fields (approximately 4.3 mm posterior to Bregma). The starting point for
sectioning was randomly determined then sections were collected systematically (section
interval of either 3 or 4). For some brains post-fixed for more than a few weeks, antigen was
retrieved by heating in a 10 mM citrate buffer (pH 8.5, temperature 80 deg C). Parvalbumin
was revealed with standard immunohistochemical methods using a monoclonal anti-
parvalbumin antibody (PV 235 mouse IgG1, Swant, Marly, Switzerland, dilution 1:800) and
a rhodamine anti-mouse secondary (Abcam, Cambridge, MA; dilution 1:200). Following
mounting and drying, sections were cover-slipped with an anti-fading medium.
To control for variations in the quality of histology and section preservation, modified
stereologically-based methods were used to determine PV+ cell density and average cross-
sectional area of the body of the hippocampus. PV+ cells were identified by their relatively
large soma lying with strata sub-pyramidale, pyramidale and oriens and the ‘baskets’
frequently formed buy their processes around pyramidal cell soma. In sections between 1.0
to 4.0 posterior to Bregma PV+ cell density was quantified using combined optical
fractionator and Cavaleri estimation methods. To estimate changes in hippocampal size
following repeated drug treatment, cross-sectional area was calculated using the Cavaleri
estimation method for each section used for PV+ cell quantification. For each brain, these
sections were aligned according to Paxinos & Franklin (2001) and the average cross-section
area for the rostrodorsal body (1.0 to 2.4 posterior to Bregma) and caudoventral body (2.5 to
4.0 mm posterior to Bregma) of the hippocampus were calculated for each brain.
Statistical Analyses—The statistical models used to analyze the data for rodent studies
are found in Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mapping a spatiotemporal pattern of hippocampal hypermetabolism and atrophy
during the emergence of psychosis
(A). Tracking changes in hippocampal cerebral blood volume (%CBV) over time in high-
risk subjects who progress to psychosis versus those who do not (‘no psychosis’) shows that
CA1 %CBV (upper graph) is increased in progressors at the pre-psychotic baseline stage
(‘Time 1’) and remains elevated at the onset of psychosis (‘Time 2’). In the subiculum
(SUB) (lower graph), no %CBV differences were observed at baseline (‘Time 1’) but an
abnormal increase emerged after the onset of psychosis (‘Time 2’).
(B) No changes in whole hippocampal volume between the progressors (‘psychosis’) and
nonprogressors (‘no-psychosis’) were observed in the pre-psychotic baseline stage (‘Time
1’) but atrophy was observed after the onset of psychosis (‘Time 2’).
(C) Changes in hippocampal morphometric shape over time between the progressors and
nonprogressors pinpoints the site of dominant hippocampal volume loss. The right and left
hippocampal bodies are shown over the posterior-to-anterior long axis, with warmer colors
indicating sites of statistically significant morphometric shape change between the groups
over time. A gradient of statistical significance over the long axis is observed, with greatest
changes observed in the anterior hippocampal body, in particular in the left CA1 and
subiculum.
(D) A vector map shows the directionality of morphometric changes between the groups.
Arrows pointing inward along the surface of the hippocampal shape indicate negative
hippocampal shape change in progressors to psychosis vs. non progressors, with the greatest
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effects observed bilaterally in the anterior CA1 and subiculum. Arrows that run parallel to
the long axis, as shown in the anterior uncus and posterior body indicate a shift in three
dimensions of the hippocampal body potentially consistent with either shrinkage or
movement of the entire structure in space over time between the groups.
See also Tables S1 and S2.
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Figure 2. Overlap of anatomical patterns of psychosis-related hypermetabolism and atrophy
(A) Magnified view of Figure 1C, showing the statistical significance p value map of
longitudinal left hippocampal body CA1 subfield morphometric shape change between
progressors and non-progressors to psychosis. The orientation from posterior (top) to
anterior is divided into representative MRI slices along the long-axis of the hippocampal
body as indicated by horizontal dotted lines corresponding with frames in Panel B.
(B) Color map of %CBV shown for a single participant acquired at baseline 24 months prior
to onset of psychotic symptoms. Illustrated are 3mm slices in the hippocampus body from
posterior to anterior of the left CA1 subfield; each frame corresponding with levels
demarcated by dotted lines in Panel A. The map shows a gradient in this individual in left
CA1, with %CBV progressively higher (warmer colors) in anterior sectors.
(C) Group-wise data of left anterior CA1 %CBV at baseline, showing differences between
patients that subsequently progressed to psychosis (progressors; (“yes”, white bars) versus
non-progressors (“no”; black bars). Each bar graph corresponds with the posterior-anterior
levels demarcated in Panels A and B. **p< 0.01 peak difference in rCBV in progressors
relative to non-progressors. Data are represented as mean ± SEM.
(D) The association between baseline left anterior CA1 %CBV and hippocampal (HIPP)
volume change. The scatterplots show data averaged from slices 1–6 shown in Panels A–C
into two posterior, middle, and anterior slices. There is a negative association between CA1
%CBV and longitudinal hippocampal volume change that becomes progressively stronger
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across the posterior-anterior axis reaching significance only in the left anterior CA1 (bottom
scatterplot; black=non progressors, white=progressors to psychosis). N=19 of the total n=25
cases are represented in the scatterplot, with n=5 lost to brain imaging follow-up, and one
case excluded due to MRI artifact preventing calculation of hippocampal CBV throughout
the long axis.
See also Tables S1 and S2.
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Figure 3. Acute ketamine administration in mice recapitulates the psychosis-associated pattern
of hippocampal hypermetabolism
Changes in hippocampal relative CBV (rCBV; see Methods for calculation) in anesthetized
mice following acute administration of ketamine (30mg/kg) are shown. Compared to saline
(black lines), ketamine (red lines) evoked significant increases in CA1 (Panel A) and
subiculum rCBV (Panel B), significant at 16min post injection. The EC (Panel C), CA3
(Panel D), and DG (Panel E) showed non-significant increases relative to saline. *p < 0.05
peak difference in rCBV, relative to saline. Data are represented as mean ± SEM.
Schobel et al. Page 21













Figure 4. Repeated ketamine administration recapitulates the psychosis-associated pattern of
hippocampal hypermetabolism and atrophy
(A) Repeated intermittent ketamine administration over one month (8mg/kg, 16mg/kg,
32mg/kg vs. saline) led to a metabolic state change in hippocampal rCBV: it dose-
dependently led to increases in basal rCBV measured at 48 hours after washout of the drug.
Statistically significant increases were observed for the 8 and 16 mg/kg repeated treatments.
* p < 0.05, relative to saline treatment. Data are represented as mean ± SEM.
(B) Compared to saline control, negative hippocampal volume change was found in mice
receiving higher doses of repeated ketamine administration, with the effect asymptoting at
16 mg/kg. ** p < 0.01; *** p < 0.01, relative to saline treatment.
(C) Rostral view of morphometric shape change map. Compared to saline control, areas of
negative hippocampal volume change were localized in the 16mg/kg group to the left ventral
aspects of hippocampal body by morphometric shape analysis; areas of statistically
significant volume loss are shown by orange clusters.
(D) Average cross-sectional hippocampal area (mm2) as measured in fixed tissue from a
subset of mice shown in Panels A–C. Relative to the saline group saline (dark bars), mice
receiving repeated ketamine 16 mg/kg (light gray stippled bars) for one month showed areal
reductions in the caudoventral aspect of the hippocampus (see main text for anatomical
boundaries). * p < 0.05 relative to saline. Data are represented as mean ± SEM. See also
Figure S1.
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Figure 5. Glutamate mediates the psychosis-associated pattern of hippocampal hypermetabolism
induced by acute ketamine administration
(A) As shown by in vivo recording of extracellular glutamate efflux performed under the
same conditions as for the imaging shown in Figure 3, acute ketamine administration (30mg/
kg) resulted in increases in evoked extracellular glutamate in CA1 and subiculum (SUB),
and not in entorhinal cortex (EC) or dentate gyrus (DG). * p < 0.05 relative to EC.
(B) The time course of the effect of acute ketamine administration in the CA1 (red line) vs.
entorhinal cortex (EC; black line).
(C) Pre-treatment with the mGluR2/3 agonist LY379268 (10mg/kg) blocked the evoked
extracellular glutamate response within the CA1 subfield.
(D) Relative to saline pre-treatment, pre-treatment with mGluR2/3 agonist LY379268
(10mg/kg) blocked the evoked rCBV response, with a trend for also reducing basal rCBV as
measured at “Time 0” (prior to the ketamine challenge).
Data for panels A–D are represented as mean ± SEM. See also Figure S2.
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Figure 6. Hippocampal hypermetabolism and volume loss induced by repeated ketamine
administration is ameliorated by a glutamate release inhibitor
(A) rCBV following repeated treatment over one month with ketamine and co-treatment
with either saline (red bars) or LY379268 10mg/kg (blue bars). Co-treatment with
LY379268 ameliorated the repeated ketamine-induced increase in basal hippocampal rCBV,
as evident from comparison with saline pretreatment. The saline/ketamine group is the same
as that previously shown in Figure 4. * p < 0.05 relative to saline.
(B) LY379268 (10mg/kg) co-treatment during repeated ketamine exposure (blue bars)
ameliorated the hippocampal (HIPP) volume loss, as evidenced by significantly preserved
(larger) HIPP volume in the LY 379268 (blue symbols) relative to the saline co-treatment
group (red symbols). ** p < 0.01 relative to saline/ketamine.
(C) Rostral view of morphometric shape change map. Pre-treatment with LY379268
resulted in protection in the CA fields of the hippocampal body as measured by MRI-based
morphometric analysis; areas of statistically significant volume protection are shown by
orange clusters.
(D) Average cross-sectional hippocampal area (mm2) in fixed brains of mice represented in
Panels A–C. Volume protection of LY379268 pre-treatment is most evident in the
caudoventral aspect of the hippocampus (see main text for anatomical boundaries).
*p < 0.05 relative to saline co-treatment ; for all groups, the saline/ketamine group is the
same as that represented in Figure 5.
Data for panels A, B, and D are represented as mean ± SEM.
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Figure 7. The effects of extracellular glutamate on PV+ interneuron density in the repeated
ketamine exposure model
(A) Intermittent repeated ketamine exposure resulted in a decrease in the apparent density of
PV+ interneurons in hippocampal CA subfields; this effect is attenuated by LY379268 co-
treatment. ** p < 0.01 Saline/Ketamine group versus saline control. Data are represented as
mean ± SEM.
(B) Decreases in PV+ expression (relative the mean of the saline control group) are
associated at trend level with increases in basal rCBV measured after one month of repeated
treatment with saline only (open symbols), ketamine with saline co-treatment (red symbols)
or ketamine with LY379268 co-treatment (blue symbols) (r=.49, p=.06).
(C) Across the same treatment groups there is a negative association between post-treatment
basal rCBV measured after drug wash-out and the change in hippocampal volumes across
the 1-month treatment period (r=.57, p=.006).
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